TDC
CPRX icon

Thompson Davis & Co’s Catalyst Pharmaceutical CPRX Stock Holding History

Thompson Davis & Co’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-24,920
Closed -$27K – 1126
2016
Q3 		$27K Sell
24,920
-26,850
-52% -$24.2K 0.05% 381
2016
Q2 		$37K Buy
+51,770
New +$41.7K 0.06% 301

Other funds holding CPRX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
TCM
Tanaka Capital Management New York $59.9M AUM
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Thompson Davis & Co's CPRX Position: Q4 2016 in Review

Thompson Davis & Co sold out of Catalyst Pharmaceutical (CPRX) in Q4 2016, closing a stake of 24,920 shares — an estimated $27K sold.

Thompson Davis & Co first reported a position in CPRX in Q2 2016 and held it in 2 quarters. The position peaked at $37K in Q2 2016. 54 funds tracked by Wall St. Rank hold CPRX as of Q4 2016.

  • Thompson Davis & Co reported no remaining Catalyst Pharmaceutical position as of Q4 2016 after selling out during the quarter.
  • Thompson Davis & Co sold 24,920 Catalyst Pharmaceutical shares in Q4 2016, an estimated $27K.
  • Thompson Davis & Co first reported a position in Catalyst Pharmaceutical in Q2 2016 and held it in 2 quarters.
  • Thompson Davis & Co's Catalyst Pharmaceutical position peaked at $37K in Q2 2016.
  • 54 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2016.

Based on Thompson Davis & Co's 13F filing for Q4 2016, filed 7 Feb 2017.